A Clinical Study on the outcome of Mehta valve implant. by Sharmila Devi, V
 1
Dissertation on 
 
A CLINICAL STUDY ON THE OUTCOME 
OF MEHTA VALVE IMPLANT 
 
 
                                 Submitted in partial fulfillment for 
 
                                       M.S. OPTHALMOLOGY 
BRANCH - III  
 
 
Regional Institute of Opthalmology 
Madras Medical College & Research Institute, 
Chennai – 600 003 
 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU Dr.M.G.R. MEDICAL UNIVERSITY 
CHENNAI – 600 003 
 
TAMIL NADU 
                                                     MARCH 2009 
 
 
 
 2
CERTIFICATE 
This is to certify that Dr.V.Sharmila Devi, Post Graduate student 
in ophthalmology, Regional Institute of Ophthalmology, Government 
Ophthalmic Hospital, attached to Madras Medical College, Chennai, 
carried out this Dissertation titled, A CLINICAL STUDY ON THE 
OUTCOME OF MEHTA VALVE IMPLANT by herself under my 
guidance and direct supervision, during the period April 2006–March 
2009. This dissertation is submitted to the Tamil Nadu Dr. MGR 
Medical University, Chennai in partial fulfillment of the award of M.S 
Degree in Ophthalmology. 
 
 
Prof.Dr.M.S.Rajarathinam, M.S., D.O., 
Chief, Glaucoma Clinic 
Regional Institute of Ophthalmology 
Govt. Ophthalmic Hospital 
Egmore, Chennai - 600 008 
 Prof.M.Radhakrishnan M.S.,D.O., 
Director and Superintendent, 
Regional Institute of Ophthalmology, 
Govt. Ophthalmic Hospital, 
Egmore, Chennai - 600 008 
 
                                                                   
Prof.T.P.Kalaniti, M.D., 
Dean, Madras Medical College & 
Government General Hospital, 
Chennai - 600003 
 3
ACKNOWLEDGEMENT 
          My sincere thanks and gratitude to Prof. Dr. T.P. Kalaniti, M.D., 
Dean, Madras Medical College for permitting me to utilize the clinical 
material of this hospital. 
I express my sincere thanks to Prof. Dr. M. Radha Krishnan, 
M.S., D.O., Director RIO GOH Madras Medical College Chennai, for his 
Valuable  guidance and constant support at every stage. 
I have great pleasure in thanking my teacher 
Prof.Dr.V.Velayutham M.S., D.O., Retired Director & Superintendent 
& Chief Glaucoma clinic. With his vast experience he has guided me 
throughout the study and made the completion of the study a reality. 
I am extremely grateful to Glaucoma clinic Chiefs’ Prof. Dr.M.S 
Rajarathinam M.S., & Prof. Dr. K.Maragatham, M.S.,D.O., for their  
guidance and support. 
          I wish to thank Dr. N.Jayanthi, M.S.,D.O., Dr.Rajini, M.S., 
Dr.N.Sharmila, M.S., Dr.R.Muthiah, M.S., for their unwavering 
support. 
I am thankful to all the professors and assistant professors who 
have guided me. 
I am also grateful to all my patients, without whose cooperation 
this study would not have been possible. 
 4
CONTENTS 
                                                                                                    PAGE NO:  
PART-1                                                                                          
1. Introduction                                                                                            6                        
2. Aqueous humor formation                                                                      7 
3. Aqueous humor outflow & anatomy  of the anterior chamber               8 
    Angle structure 
4.  Pathophysiology of drainage implants                                                13      
5.  Classification of aqueous drainage devices                                         15 
6.  Historical review of implant designs                                                   17 
7.  Outcome of glaucoma drainage devices                                              31 
8.  Comparison of implant devices                                                          34  
9.  Indication of glaucoma drainage devices                                            38 
10.Surgical technique & complications                                                   42 
 
PART-2 
1.  Aim of the study                                                                                 58    
2.  Materials and Methods                                                                       61 
3.  Results                                                                                                 74    
4.  Discussion                                                                                           84                        
5.  Conclusion                                                                                          86   
 PART-3  
     Bibliography 
     Proforma 
     Master Chart 
     Index to Master Chart 
     List of few surgeries performed 
 6
                              INTRODUCTION 
 
Glaucoma drainage devices are important tools in the management 
of Refractory glaucomas. It was introduced by Molteno in 1969 to treat 
Refractory glaucomas. They were referred to as Setons previously 
because solid structures with shaft such as threads, wires or hairs were 
placed in the wound to form a patent drainage fistula. 
         Newer drainage devices use tubes that drain aqueous out of the eye 
in to posteriorly placed external reservoirs. The GDD differ according to 
size, shape & materials from which the external component & the tube 
are constructed. 
However one of the most important fundamental design difference 
is whether the device has an open unobstructed drainage tube or one that 
contains a pressure regulating valve. Baerveldt, Molteno & Schocket are 
examples of open tube implants. Ahmed, krupin & Mehta have a flow 
restricting valve mechanism. 
In this study we describe the outcome of Mehta valve implant in 25 
cases of Refractory glaucoma. 
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AQUEOUS HUMOR 
Aqueous humor is secreted by the nonpigmented ciliary processes. 
It is derived from the plasma within the capillary network of the ciliary 
process. 
MECHANISM OF AQUEOUS HUMOR FORMATION 
1. Active transport secretion: - 70% 
An energy dependent process that selectively moves a substance 
against its electrochemical gradient across the cell membrane. 
Transports water soluble substances by Na+ k+ ATPase pump. 
Site of active transport is considered to be the nonpigmented 
epithelial cells. 
2. Ultrafiltration 
It is the movement of substance along a pressure gradient. 
Colloid osmotic pressure of tissue spaces is high. So it favours 
movement of water from the plasma in to the ciliary stroma. 
3. Diffusion 
It is the energy independent movement of substances across the 
membrane of ciliary epithelium along its concentration gradient. 
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AQUEOUS HUMOR OUTFLOW AND ANATOMY OF 
ANTERIOR CHAMBER ANGLE STRUCTURES  
AQUEOUS HUMOR OUTFLOW 
The ciliary epithelium produces the aqueous humor which enters 
the posterior chamber, passes through the pupil into the anterior chamber 
and leaves the eye by two main routes: 
(a) Conventional or canalicular system-accounts for 83% to  
90% of aqueous outflow. It consists of the following: 
1. Trabecular meshwork  
2. Schlemm’s Canal  
3. Intrascleral or collector channels and   
4. Episcleral and conjunctival veins  
(b) Unconventional or uveoscleral and uveo-vortex system- 
Accounts for 5- 15% of aqueous outflow.  
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ANATOMY OF THE ANGLE STRUCTURES 
1. Scleral spur - On gonioscopy it appears as thin prominent white 
line that is the posterior portion of the scleral sulcus. It may be 
obscured from view by dense uveal meshwork. It represents the 
location for attachment of the corneoscleral meshwork anteriorly 
and the ciliary body (longitudinal muscle) posteriorly. 
2. Trabecular Meshwork — It is a sieve like structure in the angle 
of the anterior chamber which converts the scleral sulcus into a 
circular channel called schlemm’s canal and is divided into three 
portions.  
(a) Uveal  meshwork - It is the innermost portion arranged in rope  
— like trabeculae that extend from iris root to the schwalbe’s line. 
The intertrabecular spaces are relatively large and offer little 
resistance to the passage of aqueous (25 —75 mic m openings).  
(b) Corneoscleral mesh work — It forms the middle portion 
which extends from the scleral spur to Schwalbe’s line and consists 
of trabecular sheets perforated by elliptical openings (5-50 mic. m 
in diameter)  
(c) Juxta Canalicular tissue — It is the outermost portion which 
consists of connective tissue lined on either side by endothelium. 
Outer layer comprises the innerwall of Schlemm’s Canal, while 
inner layer is continuous with the remainder of the trabecular 
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endothelium. It offers the major proportion of resistance to aqueous 
outflow.  
Gonioscopically, the trabecular meshwork consists of the following 
two parts: 
(1) The anterior nonfiltering, nonpigmented part lies posterior to 
the schwalbe’s line. 
(2) The posterior, filtering pigmented part lies adjacent to the 
scleral spur.  
(3) Schlemm’s Canal-It is an endothelial lined circular channel 
that runs circumferentially around the globe with a diameter 
of 190- 370 mic. m. Its outer wall contains the openings of 
the collector channels.  
(4) Collector Channels: They arise from the outer wall of the  
Schlemm’s canal and drain into intrascleral, episcleral and 
conjunctival venous plexus. Schwalbe’s Line-Located at the 
termination of Descemet’s membrane. It consists of a 
circumferential ring of collagenous fibres and basement 
membrane material. It marks the forward limit of the anterior 
chamber angle structures and serves as the anterior 
attachment site for the trabecular mesh work.  
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PATHOPHYSIOLOGY OF DRAINAGE IMPLANTS 
All modern implants have the same basic design which typically 
consists of a silicone tube that extends in to the anterior chamber to a 
plate, disc or encircling element beneath the conjunctiva or tenons. 
             The edge of the external plate has a ridge through which distal 
end of the tube inserts on to the upper surface of the plate. The plates 
have large surface area & promote the formation of filtering bleb 
posteriorly near the equator. 
            The mechanism by which the drainage implants controls the IOP 
relates to a fibrous capsule that forms a filtering bleb around the external 
portion of the draining device. 
            The bleb histology has been studied in the rabbit model.  After 
insertion of the device thin collagenous capsule surrounded by 
granulomatous capsule is present at one month. The granulomatous 
reaction resolves after four months. Capsule thickness remains relatively 
stable & the collagen stroma becomes less compact.  
          The fibrous capsule matures over time & becomes thinner over 
time. Microcystic spaces within thick layer of connective tissue in the 
 14
bleb may serve as channels of aqueous drainage. All surface of the 
fibrous Capsule contribute to filtration. 
There is a direct relationship between the surface area of the 
implant & the filtering capacity of the surrounding capsule. At the same 
time reduction of the bleb diameter decreases capsular tension on the 
bleb, capsular fibrosis & thickness which increases the effectiveness of 
the filtering surface. 
            The failure of the filtering bleb after surgery may occur due to the 
increased thickness of the fibrous capsule around the implant. 
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AQUEOUS DRAINAGE DEVICES 
• SETONS   
• SHUNTS 
• VALVES 
SETONS 
Non hollow linear shaft prevents wound apposition.  Allows bulk 
flow by surface tension. 
Horse hair                   Tantalum wire 
Gold wire                     T- tube 
SHUNTS 
            They are passive tubular structures 
            Molteno 
            Baerveldt 
            Schocket 
           White pump shunt 
 16
 
 
 
 17
VALVES 
Valves allow unidirectional flow. The valves available are 
Krupin Denver 
Ahmed glaucoma valve 
Optimed pressure regulator 
Joseph valve 
Mehta valve 
HISTORICAL REVIEW & IMPLANT DESIGNS 
MOLTENO IMPLANT 
In 1969 the Molteno implant was used to treat Refractory 
glaucomas. It’s a prototype drainage implant & it consists of a single 
plate of thin acrylic with a diameter of 13mm & an area of 135sq mm. A 
Silicone tube with an external diameter of 0.62mm & internal diameter of 
0.3mm connects to the upper surface of the plate. 
      A double plate Molteno combines two plates one of which is attached 
to the silicone tube in the anterior chamber while a second tube connects 
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the two plates giving a surface area of 270sq mm. Success rates with the 
double plate Molteno implant rose when compared to single plate. 
Molteno’s key discoveries 
¾ Implant to be made of non reactive synthetic material, with poor 
fibroblastic adherence 
¾ Its essential to establish a potential space for aqueous pooling 
¾ Bleb should be away from limbus at the equator. 
VARIATION OF MOLTENO TECHNIQUE 
¾ One-plate or two-plates 
¾ One-stage or two-stage procedures 
¾ Fibrosis suppression using medications 
¾ Tube placement under scleral flap or donor graft 
¾ Suture occlusion of tube internally or externally 
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                           BAERVELDT IMPLANT 
 
 
 
                         SCHOCKET TUBE SHUNT 
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       BAERVELDT PARS PLANA IMPLANT 
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BAERVELDT IMPLANT 
The unique feature of this implant is the large surface area of the 
plate. It works on the dose response between surface area & IOP. A 
Silicone tube is attached to a soft silicone plate. 
THREE SIZES AVAILABLE : 
 200sq mm (13 x 20 mm) 
 350sq mm (14 x 32 mm) 
 500sq mm (17.5 x 36 mm) 
However the 350sq mm implant is the preferred size & its safer & 
more effective than the 500sq mm implant. 
The plate has fenestrations that allow growth of fibrous tissue 
through the plate serving to reduce the height of the bleb & secures the 
implant in place. 
SCHOCKET TUBE SHUNT 
Schocket developed a technique in which a silicone tube is 
extended from the anterior chamber through a 360 degree encircling 
silicone band as used in retinal detachment repair. 
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Modifications include insertion of the tube into a band extending 
for only 90 degrees beneath two recti or in to the pre-existing encircling 
band. 
Though the shunt has a larger surface area than the Molteno 
implant, comparative  studies show that the Molteno implant had a lower 
final IOP. 
 23
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FLOW RESTRICTED DRAINAGE DEVICES 
AHMED GLAUCOMA VALVE 
In this valved implant design silicone tube is connected to a 
silicone sheath valve which is held in a polypropylene body. The body of 
the most commonly used S2 model has a surface area of 184sq mm 
(16*13mm) & is 1.9mm thick. It works on the venturi effect. 
The valve mechanism consists of 2 thin silicone elastomer 
membranes 8mm long &7mm wide.It allows one way regulation of flow 
with  IOP between 8mm Hg &10 mmHg in the postoperative period. 
The critical site for pressure drop is at the capsule surrounding the 
implant. Ahmed implant as with other implants has a hypertensive phase 
which is a transient phase of low capsule permeability seen at 4 to 8 
weeks postoperatively. 
      The S2 model is made of polypropylene & the FP7 model is made of 
silicone. Silicone appears to cause cause less inflammation. Special 
modifications are available with pars plana clip for pars plana insertion. 
Two trials investigating the effectiveness of adjunctive mitomycin 
(MMC) with the Molteno and Ahmed implants found no evidence of 
benefit with MMC. 
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ADVANTAGES: 
z Immediate IOP reduction 
z  Reduced incidence of Hypertensive phase post operatively 
z Unique pressure sensitive valve to prevent excessive drainage & 
chamber collapse 
z Single stage implantation 
z Eliminates drainage tube ligature sutures, Rip-cord & occlusion 
sutures. 
OTHER DRAINAGE DEVICES 
The Joseph tube with slit valve in its side is calibrated to open     
between 4 & 20mm Hg attached to 9mm wide silicone rubber strap. The 
other shunts available are Optimed glaucoma pressure regulator & White 
pump shunt that may be activated by touching or blinking.  
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OPTIMED GLAUCOMA PRESSURE REGULATOR 
Made of PMMA & Silicone. Has 2 parts… 
1. Inlet tube 
2. Pressure regulator component 
Overall length 17.78mm 
Width 5mm 
Outflow pressure 10mm Hg 
A variety of new stents & shunts are now available for refractory 
glaucomas. They are 
1. Express miniature glaucoma shunt from Optanol 
2. Mini catheter from iScience 
3. iStent from Glaucos 
4. Deeplight Gold microshunt from SOLX 
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EXPRESS SHUNT 
Optonol's Ex-Press shunt developed in Israel is an effective, long-
term alternative to traditional glaucoma surgery and can significantly 
improve the quality of life of glaucoma patients by providing possible 
relief from life-long dependency on drug therapy. 
The FDA-approved shunt is a miniature glaucoma drainage device, 
just the tiny spike at the end of the needle. A simple, short procedure 
inserts the shunt at the edge of the colored part of the eye, the limbus. The 
microscopic conduit works by bypassing the blocked trabecular 
meshwork allowing aqueous to drain from the AC into the intrascleral & 
Subconjunctival spaces where it is absorbed by the blood vessels.                                     
The 3-mm long, 400 micron diameter implant has received both 
Food and Drug Administration approval and CE approval for marketing 
in Europe. Before its introduction into the US market, the device had 
been implanted in more than 1,200 human patients since 1997 in 
worldwide clinical trials and in commercial use in Europe. 
2. i Science mini catheter 
The minicatheter is inserted into the canal of Schlemm in a 
procedure similar to viscocanalostomy. 
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                                  GLAUCOS iSTENT 
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3. Glaucos istent 
The istent from Glaucos Corporation is a small spike like implant 
that is inserted across the anterior chamber into the trabecular meshwork. 
It is designed to allow aqueous to enter the canal of Schlemm. The 
device is very small with a width of 80 microns & a length of 1mm. 
          A goniolens is used to view the angle while moving the istent 
across the anterior chamber.There are some practical difficulties as the 
stent has to be placed correctly in the Schlemm’s canal 
4. SOLX Deep Light Gold Microshunt 
The 24 carat deep light gold microshunt from SOLX is designed to 
lower IOP in a procedure without a bleb.The implantable device reduces 
IOP by taking advantage of the natural  pressure differential between the 
anterior chamber & the suprachoroidal space (SOLX literature). 
The ultra thin device is inserted into a 4mm wide incision that 
connects the anterior chamber to the suprachoroidal space. The shunt is 
biocompatible, inert, rests permanently in the suprachoroidal space &  
can eliminate the formation of scar tissue according to company 
literature.  
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BIFURCATABLE TRABECULAR SHUNTS 
The claims about the shunt: 
A trabecular shunt for transporting aqueous humor in an eye, 
comprising an elongated tubular element having an inlet section and an 
outlet section; wherein the outlet section comprises two bifurcatable 
elements, the bifurcatable elements configured to be positioned within a 
Schlemm's canal of the eye, wherein at least one of said two bifurcatable 
elements comprises a shape-memory material, the shape-memory 
material having a preshape and a shape-transition temperature, wherein 
the shape memory material conforms to its preshape when the shape-
memory material is heated to above the shape-transition temperature; and 
an external heat source that is adapted to heat the shape-memory material 
to above the shape-transition temperature. 
The method may further comprise placing the trabecular shunt 
inside a delivery apparatus, wherein the two bifurcatable elements are 
self-bifurcatable in two opposing directions when the trabecular shunt is 
deployed from the delivery apparatus. 
The trabecular shunt may include a pressure sensor for measuring 
the pressure of the anterior chamber of an eye of a patient. The pressure 
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sensor may further include an electromagnetic (e.g., radiofrequency) 
transmitter, for wirelessly transmitting pressure measurements to a 
pressure receiver outside the patient's body. 
Outcome of glaucoma drainage devices 
The following data are derived from the long term follow ups of 
study populations in which “success” was typically defined as lower end 
cut off of 5-6mmHg & high end of 21-22 mmHg with or Without 
medications. 
In Trials with Molteno implant success rates were 73-74% with   a 
minimum follow up of 18 months & 57% with a mean follow up of 43-44 
months. Survival analysis in a retrospective study showed that failure was 
most common in the first post-operative year & significant risks for 
failure were pseudophakia & Neovascular Glaucoma. Postoperative IOP 
tended to be lower after double plate than after single plant implantation. 
With Shocket type implants success rates were 81% with a 17.5 
month mean follow up but fell to 30% at 36 months in one study. 
Reported success rate with Baerveldt implants were 93% & 88% 
for 350 sqmm implant & 500sqmm implant respectively. 
 32
Studies with Krupin valve revealed a success rate of 66% after 12 
months & 80% success rate after 25 months. 
Studies with Ahmed valve reveals success rates of 77-88% at1year 
of follow up & 75% success rates at 2 years of follow up. However in 
paediatric population success rate is somewhat lower.  
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BLEB AFTER  IMPLANT PROCEDURE 
 
  
 
 
 
AGV   IN PSEUDOPHAKIC GLAUCOMA 
 34
COMPARISON OF IMPLANT DEVICES 
Device Ahmed 
S2 
Ahmed 
FP7 
Molteno 
D1 
Baerveldt BG 
103 250 
Baerveldt 
BG 101 
350 
Mehta 
Surface area(mm2) 184 184 133 250 350  
Side to side(mm 13 13 13 22 32 15 
Front to back(mm) 16 16 13 14 15 17 
Implant 
profile(mm) 
1.9 0.9 1.65 0.84 0.84  
Single quad 
insertion 
yes yes yes yes yes yes 
Plate Material Rigid 
polypro
pylene 
Smooth 
silicone 
Rigid 
polypropyl
ene 
Smooth 
silicone 
Smooth 
silicone 
Smoot 
silicon 
Drainage tube valved valved open open open Valved 
Fixation suture 
holes 
yes yes yes yes yes Yes 
manufacturer New 
world 
medical 
New 
world 
medical 
Molteno 
opth, ltd 
Advanced med 
optics 
Advanced 
med optics 
Surgiw
ear 
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KEIKI MEHTA “BP VALVE” GLAUCOMA SHUNT 
INTRODUCTION: 
Keiki Mehta “BP valve” glaucoma shunt has been developed by 
Surgiwear in association with Dr. keiki R. Mehta world renowned 
Ophthalmic surgeon. It is a very simple & effective device which has no 
high sounding mechanics or valves. It has just three parts a tube, a 
membrane valve & a button, all made of medical grade silicone. It has 
following important features. 
A. “BP Valve” or body pressure valve.  
The valve regulating the flow does not have any opening pressure of 
its own. It is being pressed by body’s own tissues. When the pressure of 
fluid in eye is more than pressure of body tissues, the valve will open & 
allow flow of fluid. Thus the fluid pressure inside the eye is maintained at 
the level of body pressure. 
B. “Peaks on button” there are multiple peaks on the button. These 
peaks keep conjunctiva and Tenon’s capsule away from button 
to facilitate distribution of fluid around. These peaks allow 
fibrous growth & hence it prevents plate migration. The fluid can 
pass beyond the button also, because there is no limiting ridge 
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around. Thus effectively it has a large absorption area for the 
fluid to get absorbed. 
C. Soft & flexible button with rough upper surface. The button 
body is soft so easy to implant. The rough top surface creates 
large surface area & prevents sticking of valve with button body. 
PRESENTATION 
The glaucoma shunt is available sterilised ready to use in three sizes: 
1. Regular size 
2. Small size 
3. Large size. 
Depending upon size of the eye ball & severity of problem the size 
is selected. 
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INDICATIONS 
Indications of GDD: 
         Drainage implant surgery is reserved for patients in whom 
trabeculectomy with adjunctive anti-metabolite has either failed or is 
thought to have a very low chance of success or in whom still there is a 
reasonable potential for vision. 
1. Young patients- in children with JRA & Uveitic Glaucoma. 
2. Intractable Neovascular glaucoma. 
3. Glaucoma associated with Uveitis. 
4. Severe Conjunctival scarring. 
5. Glaucoma in aphakia & pseudophakia 
6. Patients with prior surgery such as vitreo retinal surgery & PKP. 
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YOUNG PATIENTS 
          Drainage implant surgery for childhood glaucoma is more 
problematic than in adults. Nevertheless success rates of 55-95% have 
been reported with no definitive advantage between Molteno, Baerveldt 
or Ahmed. 
          Drainage implant surgery may be especially useful in children with 
juvenile rheumatoid arthritis & uveitic glaucomas & glaucomas 
associated with Sturge-Weber syndrome. 
           An advantage of drainage implants over trabeculectomy with 
antimetabolites in Sturge-Weber is the reduced risk of expulsive 
haemorrhage associated with marked IOP reduction. 
           Complications in chidren include tube malposition, flat anterior 
chamber, tube obstruction by iris or vitreous, cornea tube touch, choroidal 
detachment, corneal oedema & corneal abrasion. 
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NEOVASCULAR GLAUCOMA 
          Drainage implants have been successful in some eyes with 
neovascular glaucoma, although the success declines with time. 
Glaucoma drainage implants have been reported to have better outcome 
in the eyes with neovascular glaucoma than cyclophotocoagulation. 
UVEITIC GLAUCOMA 
         Ahmed valve implants have been shown to be a better alternative 
for high risk patients with uveitic glaucoma. Success may be enhanced by 
preop & long term postop immunotherapy. 
SEVERE CONJUNCTIVAL SCARRING AND PREVIOUS 
OCULAR SURGERY 
          A failed trabeculectomy, especially when the conjunctiva is scarred 
down in both superior quadrants, could be an indication for a drainage 
implant procedure. Schocket implants have been used in association with 
pars plana vitrectomy in eyes with vitreoretinal disorders. 
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ANIRIDIA 
Molteno implants & the Ahmed valve have been used in these 
patients. These are the general indications of GDD. Mehta valve implant 
is indicated in Neovascular, Congenital & uveitic Glaucoma. 
 42
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SURGICAL TECHNIQUE OF MEHTA VALVE IMPLANT 
1. Priming of the valve is done by injecting saline through a 
27guage needle in to the tube. This is done to expel the air 
bubble in the tube & the patency of the shunt is also checked by 
flushing the tube. 
2. A fornix based incision is given either in supero nasal or supero 
temporal quadrant & conjunctiva is opened. 
3. A pocket is created under conjunctiva & tenons with curved 
corneal scissors. 
4. A curved blunt spatula is used to further clear the pocket. 
5. A glaucoma shunt is inserted in to the pocket created under the 
conjunctiva & tenons. 
6. The valve has two eyelets & it is sutured in place using 10-0 
monofilament nylon. 
7. A graded micro metre knife is used to make two cuts deep in to 
sclera to bury the tube & 1.2mm diamond knife is used to create 
the passage through the sclera in to the anterior chamber. 
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8. Length of the tube is calculated & it is cut with the bevel facing 
up. Length should be sufficient to enter in to the anterior 
chamber. 
9. The tube is pushed through the intrascleral tunnel. The end of 
the tube should be visible in the anterior chamber. 
10. Conjunctiva is closed using absorbable suture. 
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OTHER MODIFICATIONS OF BASIC TECHNIQUE 
Sometimes the conjunctiva is scarred at the limbus, making 
conjunctival dissection impossible without destroying much of the 
conjunctival tissue. In this case, the initial   conjunctival incision may be 
made approximately 8mm from the limbus to create a limbal based 
conjunctival flap. Another option is to use the inferotemporal or a 
superonasal quadrant. 
            Sometimes occlusion ligatures like releasable sutures can be tried. 
Biodegradable stents like collagen lacrimal plugs or 4-0 chromic sutures 
also have been evaluated but they have been less satisfactory because 
they do not always resolve. 
            A clear corneal graft tied with 8-0 nylon can be used instead of 
pericardium or scleral graft to cover the outer portion of tube. 
          Instead of preserved tissue an autologous partial thickness scleral 
patch graft crafted from the sclera adjacent to the tube has been 
described. 
           No complication has been described with this technique but the 
risk of perforation to the globe exists. 
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           Some use stent occlusion with longitudinal slits in the tube to 
provide early IOP control. 
            In a retrospective study implantation of AGV with the use of 
MMC achieved lower postoperative IOP with fewer glaucoma 
medications. However at the present time there does not appear to be 
significant benefits from application of antimetabolites in conjunction 
with drainage implant. 
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COMPLICATIONS 
            The complications associated with aqueous shunts can be 
categorised as those associated with the reduction of IOP, with the 
functioning and placement of the tube, with the episcleral plate and the 
response to surrounding tissues to it, and with the intraocular surgery per 
se. 
Complications associated with reduction of IOP 
HYPOTONY 
            Flat anterior chamber has been reported following insertion of 
valved and nonvalved aqueous shunts. Until the fibrous capsule has 
developed around the aqueous flow the open non valved tube implants 
provide very low resistance to flow and hypotony in early post op 
course.The best way to prevent this postop complication is by temporarily 
obstructing the tube lumen. 
           Techniques include suture ligation of the tube, temporary 
occlusion of the tube lumen with a stent, 2 stage implantation or use of a 
valved implant. If early post op hypotony happens with flat AC then 
injection of dense viscoelastic in to the AC & close observation may be 
helpful. 
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          If hypotony persists then removal of the tube from the AC is 
recommended to prevent corneal decompensation, Repositioning can be 
done later. 
Treatment of Early Postoperative Hypotony 
Most early postoperative hypotony is sell-limited and will resolve 
spontaneously without treatment. However, intervention is warranted 
when there is lens-cornea touch or when there is evidence that the 
hypotony will be prolonged if no intervention is made.  
Identify and repair any bleb leaks which result in significant 
hypotony associated with a flat chamber. A small leak may be observed if 
the chamber is adequately maintained allowing time for spontaneous 
closure.  
Deepen the chamber with viscoelastic through the paracentesis if 
there is lens-cornea touch. This procedure can be repeated daily until the 
lOP begins to rise and the chamber stabilizes (usually at the end of week 
two).  
Drain large choroidals if there is lens-cornea touch. This will 
deepen the chamber and expedite the return to a normal IOP.  
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                            TUBE EXPOSURE 
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Elevated IOP 
           Elevated IOP can be present in the early or late postop period. 
Within the first 7-10 days there is a hypotensive phase followed by a 
second hypertensive phase associated with formation of fibrous capsule. 
The IOP reduction & stabilisation occurs in the next 3-6 months. Elevated 
IOP in the early post op period may be due to obstruction of the tube by 
fibrin, blood, iris, vitreous membranes. This is been observed in 11% of 
case after the AGV implant. 
Iridectomy at the site of the tube ostium has been recommended to 
prevent iris plugging the tube ostium. Nd YAG laser membranectomy 
was effective for reopening blocked glaucoma tube shunts but the risk of 
recurrence is high. Another technique is to irrigate the tube with BSS 
using a 30 guage cannula through a paracentesis incision. Intracameral 
injection of TPA is done to resolve fibrin clot. 
Late IOP elevation inspite of the tube being patent is due to 
excessively thick fibrous capsule. Needling revision can be done in such 
cases. It is been reported that topical steroid therapy can cause IOP 
elevation despite the presence of a drainage implant. 
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Treatment of Early Postoperative Hypertension  
Observation for first 48 hours if not severe. The IOP will 
frequently come down spontaneously as viscoelastic, blood, fibrin, or 
other occlusive material is cleared from the anterior chamber.  
If the IOP is unacceptably high, the addition of digital massage or 
antiglaucomatous medications may be useful. This will allow time for an 
absorbable suture ligature to dissolve or for bleb encapsulation to occur 
allowing removal of the tube occluding (stent) suture.  
Remove the occluding (stent) suture; if this is done during the first 
week, the chance of severe hypotony, shallow chamber, and related 
complications is increased.  
If the end of the tube is occluded by vitreous, iris, or fibrin. The 
Nd: Yag laser may be used to clear the obstruction. In some cases, a 
return trip to the operating room may be necessary. This is particularly 
common if there is a large anterior hyphema in the early post-operative 
period which is associated with significant IOP elevation.  
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MIGRATION, EXTRUSION & EROSION 
Tube migration may occur after glaucoma shunt procedures. If the 
tube is not adequately secured to the sclera it may migrate posteriorly out 
of the anterior chamber, which may require repositioning of the tube & 
securing it to the sclera with additional 9-0 prolene sutures. 
Extrusion of the implant was the most common reason for repeat 
surgery in children. The tube may need to be repositioned when it is 
blocked by cornea, iris, or vitreous. Avulsion of an implant after blunt 
trauma may force the tube against the cornea, causing corneal melting & 
requiring explantation of the implant. 
          Erosion of the silicone tube through the overlying conjunctiva is a 
recognised complication of the aqueous shunts. A partial thickness scleral 
flap does not prevent erosion of the tube. The tube & fistula site should 
be covered with preserved sclera, dura, fascia lata, or pericardium. 
           If a scleral graft is too thick, it may elevate the limbal conjunctiva 
enough to produce dellen formation. 
           Solvent preserved cadaver pericardium offers several advantages, 
including availability, lower cost, uniformity in size & tissue quality & 
enhanced sterility. Tissue sterilisation is achieved through the treatment 
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with organic solvents followed by low dose radiation, which inactivates 
bacteria, fungi &viruses including HIV. 
ENDOPHTHALMITIS 
          Endophthalmitis may develop after needling of implant. Recurrent 
Propionibacterium acnes endophthalmitis has been reported after molteno 
tube revision. 
           Tube reinsertion in to the anterior chamber resulted in recurrence 
of the infection. Early postoperative endophthalmitis, following 
placement of an implant, may be successfully treated by immediate 
removal of the implant & surgical management of the infection, with 
subsequent placement of a new implant. 
          In the late post-op period exposure of the tube seems to be a major 
risk factor for these infections. Surgical revision with a patch graft in all 
cases in which there is an exposed tube is indicated to prevent this 
potentially devastating complication. 
CORNEAL DECOMPENSATION & GRAFT FAILURE 
            Tube-cornea touch is a cause of corneal decompensation. When 
the tube-corneal contact is seen, removal of the tube from the anterior 
chamber, shortening of the tube, & subsequent reinsertion may be 
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necessary. Corneal problems may be secondary to the underlying ocular 
condition or to the drainage itself. Phosphorylcholine polymer coating of 
the glaucoma drainage devices was suggested to reduce the rate of 
corneal endothelial failure. 
DIPLOPIA & OCULAR MOTILITY DISTURBANCE 
           Implants with larger plates, especially when implanted in the 
superonasal quadrant, can interrupt extraocular muscle function & cause 
strabismus & diplopia. While the complication is usually associated with 
the larger plates, such as the 350 sqmm Baerveldt implant & the Krupin 
valve with disc, it may also occur with smaller plates, such as the single-
plate or double-plate Molteno implants, especially in children. 
Corrective measures may require removal of the implant, 
replacement with a smaller plate design or transfer to the superotemporal 
quadrant, which usually relieves the implant. 
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AIM OF THE STUDY 
To measure the outcome of Mehta valve implant in 25 cases (26 
eyes) of intractable glaucoma inserted using a modified surgical 
technique that eliminates the need for a donor scleral graft. 
The main outcomes included   
1. Analysis of intraocular pressure control following surgery & 
comparison with the preoperative baseline IOP 
2. Frequency of intraoperative and postoperative complications. 
3. Success rate of the procedure at a follow up of 6months, 1year, 18      
Months &2years    
 59
INCLUSION CRITERIA 
Patients between the ages of 30-70 yrs were taken. One patient 
alone was in the paediatric age group. 
Patients with Glaucoma uncontrolled on maximum tolerated 
medical therapy & were considered at high risk of failure for 
trabeculectomy or had previously failed trabeculectomy were taken. 
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     POST INFLAMMATORY GLAUCOMA 
 
        NEOVASCULAR GLAUCOMA WITH NVI 
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MATERIALS AND METHODS 
A total of 26 eyes of 25 patients diagnosed as refractory Glaucoma 
attending the Glaucoma service of GOH between August 2006 & October 
2008 were enrolled in this study. 
Of the 25 cases 18 cases were neovascular glaucoma, 2 were cases 
of post-traumatic Glaucoma, 2 were cases of post traumatic glaucoma 
with failed trabeculectomy, 2 cases were postinflammatory glaucoma &1 
case of post PKP glaucoma. 
All the patients included in this study were adviced to come for  
regular follow up visits in our clinic. Diagnosis of glaucoma was mainly 
based on changes in the optic discs and intraocular pressure (By 
Applanation tonometry) & Gonioscopic findings. 
All the surgeries were performed by single surgeon. Indications for 
valve insertion included intraocular pressure not controlled by medical 
therapy or other forms of surgery—namely, cycloablation and  
trabeculectomy. 
Implant used was Keiki Mehta BP valve Glaucoma shunt 
developed by surgiwear in association with Dr. Keiki.R.Mehta. The 
Glaucoma shunt is available sterilised ready to use in 3 sizes: 1.Regular 
size, 2. Small size, 3.Large size. 
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              INTRA OPERATIVE PICTURES 
 
 
     IMPLANT PROCEDURE IN POST PKP GLAUCOMA 
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SURGICAL TECHNIQUE OF MEHTA VALVE IMPLANT 
1. Priming of the valve is done by injecting saline through a 
27guage needle in to the tube. This is done to expel the air bubble in 
the tube & the patency of the shunt is also checked by flushing the 
tube. 
2. A fornix based incision is given either in supero nasal or supero 
temporal quadrant & conjunctiva is opened. 
3. A pocket is created under conjunctiva & tenons with curved 
corneal scissors. 
4. A curved blunt spatula is used to further clear the pocket. 
5. A glaucoma shunt is inserted in to the pocket created under the 
conjunctiva & tenons. 
6. The valve has two eyelets & it is sutured in place using 6-0 
prolene. 
7. Intrascleral tunnel is created about 3mm from limbus using 18 
guage needle & the needle is used to enter the anterior chamber 
8. Length of the tube is calculated & it is cut with the bevel facing 
up. Length should be sufficient to enter in to the anterior chamber. 
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9. The tube is pushed through the intrascleral tunnel. The end of the 
tube should be visible in the anterior chamber. 
10. Conjunctiva is closed using absorbable suture. 
             In the original surgical technique described by Dr. Keiki Mehta a 
graded micro metre knife is used to make two cuts 35 micron deep in to 
sclera to bury the tube & 1.2mm diamond knife is used to create the 
passage through the sclera in to the anterior chamber. 
But here the Surgeon used an intra scleral tunnel using an 18 guage 
needle to insert the tube. 
All cases were done without patch graft& tube was secured in the 
intrascleral tunnel. This eliminated the complications associated with the 
patch graft. 
Definition of Success: 
A Postoperative IOP between 8mmHg & 21mmHg without 
medications was termed successful. Qualified success was defined as an 
IOP between 8 & 21mmHg with additional topical medications. 
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Failure was defined as persistent IOP >21mmHg, 
hypotony<8mmHg, a requirement for cyclodestructive procedure or 
further glaucoma surgery. 
A transient elevation of IOP was permitted if the mean IOP for a 6 
month period was less than 21mmHg. If it remained elevated the time of 
failure was taken as the first date the elevation was recorded. 
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Demographics of study population: 
NUMBER 
  Patients 
  Eyes 
NO 
25 
26 
AGE 
 0-10 
30-40 
40-50 
50-60 
60-70 
No- % 
1-  4% 
4-   16% 
4-   16% 
12-  48% 
4-    16% 
Pre-op IOP 
20-30 
30-40 
40-50 
 
1 
17 
8 
Diagnosis 
Neovascular Glaucoma 
Post-traumatic Glaucoma 
Post PKP Glaucoma 
Post traumatic Glaucoma 
Post inflammatory Glaucoma 
No of eyes 
18 
2 
1 
2 
3 
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Previous Glaucoma Surgery 
Total 
 
3 
Type of previous Glaucoma 
surgery 
Trabeculectomy 
Cyclocryotherapy 
 
 
2 
1 
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AGE DISTRIBUTION 
Age in years No of cases %age 
0-10 1 4 
30-40 4 16 
40-50 4 16 
50-60 12 48 
60-70 4 16 
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GENDER DISTRIBUTION 
SEX No of cases % age 
MALE 15 60 
FEMALE 10 40 
 
 
LATERALITY 
Laterality BE RE LE 
No. 1 14 10 
% age  4 56 40 
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 72
 
 
                         LATERALITY 
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          MEHTA VALVE IMPLANT IN A CASE OF POST 
                       TRAUMATIC GLAUCOMA    
 
 
       MEHTA VALVE IMPLANT IN A CASE OF NVG 
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RESULTS 
Mehta valve implantation was done in 26 eyes of 25 patients 
during the 2 year study period between September 2006 & October 2008. 
The male to female ratio was 2:1 & the mean age was 48.06(range 
10-64 yrs). 
The mean pre-operative IOP   was 37.4mmHg. 
Of the 26 eyes operated 18 were cases of Neovascular glaucoma. 1 
was a case of post PKP glaucoma, 2cases were of post traumatic 
glaucoma, 2 were cases of failed trabeculectomy &2 (3eyes) were cases 
of post-inflammatory glaucoma. 
In the immediate postoperative period IOP was recorded by Non 
Contact Tonometry. 
21 patients had immediate postoperative IOP well within the 
desired range. 
3 patients had minimal hyphema in the immediate postoperative 
period & the IOP was not recordable immediately but 1 week later the 
IOP was within the desired range. 
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1 patient had a persistent shallow anterior chamber with high IOP.   
The patient was taken up for surgical revision & the intumescent cataract 
was removed. The patient’s IOP remained stable throughout the period of 
follow up. 
Out of the 14 patients who had to come for followup after 18 
months only 12 patients came for regular followup. 
Out of the 12 cases one paediatric case of postinflammatory 
glaucoma had tube erosion & the valve was explanted. 
The average follow up for all eyes ranged between 6mths to 
2years.Four eyes were reviewed for 2 years. For three eyes the follow up 
was only for six months. Not all eyes were reviewed at every follow up 
period. 
At the time of last follow up 23 eyes were considered successful. 
Of the 3 eyes that failed 1 eye was a Paediatric post inflammatory 
glaucoma, 1 eye was neovascular glaucoma & the other one was post 
traumatic glaucoma with failed trabeculectomy. 
3 cases who had significant cataract were taken up for cataract 
surgery through clear corneal incision at a later date. There was no 
displacement of the tube or spike in IOP following surgery. 
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VISUAL OUTCOME 
At the patient’s last follow up visit, the visual acuity outcomes 
defined as a change of 1 or more Snellen lines was improved in 20%, an 
improvement in 1 metre observed in 20% & was unchanged in 60%. 
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GLAUCOMA DIAGNOSIS 
 
No. of Patients 
Neovascular glaucoma 18 
Post traumatic glaucoma 2 
Post PKP glaucoma 1 
Post traumatic glaucoma 2 
Post inflammatory glaucoma 2 
 
 
 
VISUAL OUTCOME 
Post-op BCVA No. of 
patients 
Visual acuity unchanged  15 
Visual acuity improvement by 1 m 5 
Visual acuity improvement by one line( Snellen’s chart) 2 
Visual acuity improvement by two lines ( Snellen’s chart) 3 
 
 
 
 78
 
                              GLAUCOMA DIAGNOSIS 
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                         VISUAL OUTCOME 
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Glaucoma 
diagnosis 
Follow up 
 6 months 1 yr 18 months 2 yrs 
No. of eyes 1 1 1 1 
Success 1 1 1 1 
Post PKP 
glaucoma 
Failure - - - - 
     
No. of eyes 18 14 6 3 
Success 17 13 5 2 
Neovascular  
glaucoma 
 
Failure 1 1 1 1 
     
No. of eyes 3 3 2 - 
Success 3 2 1 - 
Post 
inflammatory  
glaucoma 
Failure 0 1 1 - 
     
No. of eyes 2 2 2 - 
Success 2 2 2 - 
Post traumatic 
glaucoma 
Failure - - - - 
     
No. of eyes 2 2 1 - 
Success 2 2 - - 
 Post traumatic 
Glaucoma with 
failed 
trabeculectomy 
Failure - - 1 - 
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                POST OPERATIVE FOLLOWUP 
 
 
 
 82
Complications 
There were no intraoperative complications. 
4 pts with NVG had post op hyphaema which resolved with 
conservative management. 
Another patient who was diagnosed as RE NVG with mature 
cataract required surgical revision as the AC was very shallow 
postoperatively with high IOP. The cataract was removed through clear 
corneal incision and AC was reformed. The patient had stable IOP 
through out the period of follow up. 
A paediatric patient diagnosed as a case of postinflammatory 
glaucoma underwent Mehta valve implantation in BE. He had erosion of 
tube through conjunctiva in RE after 15months & the shunt was 
explanted. 
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DISCUSSION 
Trabeculectomy despite recent modification and use of 
antiproliferative agents still fails to control intraocular pressure in some 
cases of refractory glaucomas. Remaining surgical options include 
cyclodestructive & drainage implant procedure. 
Since the introduction of Molteno implant there has been a rapid 
advancement in the drainage devices used & improvement in the surgical 
techniques. 
Studies with Ahmed valve reveals success rates of 77-88% at 1year 
of follow up & 75% success rates at 2 years of follow up. However in 
paediatric population success rate is somewhat lower. 
In the study group there was a significant reduction in the mean 
IOP following surgery which was sustained over the duration of follow 
up & was associated with the decrease in the number of glaucoma 
medications required. 
There were no intra-operative complications. Only one case had 
displacement of the tube & conjunctival erosion. The partial thickness of 
the scleral tunnel used in this technique proved sufficient to prevent 
conjunctival dehiscence & tube exposure. The implant was secured nicely 
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between the two recti and hence extra ocular muscle function was not 
interrupted post operatively and there was no strabismus. 
Using strict definition of success our qualified success rates are 
96% for the first 6 months 90.9% for the first 1 year & 75% for the first 
18 months. 
Only 4 cases were followed up for 2 years & the success rate for 
the 2 year follow up period was 75%. 
The mean pre-operative IOP   was 37.4mmHg. The mean post-
operative IOP at 1 year was 16.04, 17.7 at 18 months & 16.8 at 24 
months including the failures. 
Longer follow up is necessary to examine the long term course of 
the success rate. However previous studies suggest that longer follow up 
almost always leads to decrease of surgical success, whether the surgical 
procedure is glaucoma implant surgery, trabeculectomy or cycloablation. 
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CONCLUSION 
In terms of IOP control Mehta implant was found to be good in 
patients with uncontrolled complicated glaucoma cases. The fall in IOP 
was sustained over the period of follow up. 
It is a valved implant & hence it prevents post operative hypotony 
by providing resistance to the flow & therefore regulating the pressure 
within the desired range. 
All cases were done without patch graft & tube was secured in the 
intra scleral tunnel. 
In conclusion, Mehta valve implant is a simple & an effective 
device & it could be a good treatment option in intractable glaucomas. 
Nevertheless longer follow up is necessary to examine the long term 
course of the success rate. 
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PROFORMA 
 
SL.NO: 
 
NAME:    GLAUCOMA CLINIC NUMBER: 
 
AGE:                            DATE : 
 
SEX:               
 
AFFECTED EY   :  PRESENT / ABSENT  
            
HYPERTENSION  : PRESENT / ABSENT  
 
OCULAR EXAMINATION :       DATE OF SURGERY: 
 
Vision:   
                   
IOP by applanation:   POST OP PERIOD 
 
Conjunctiva: 
 
Cornea:      FOLLOW UP 
 
AC:       IOP  
 
Iris:       BCVA 
 
Pupil:      Any Complication 
 
Lens: 
 
Gonioscopy: 
 
Field: 
 
Fundus: 
 
B- Scan: 
 
Diagnosis( Type of Glaucoma) : 
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                INDEX TO MASTER CHART 
 
 
1.  BCVA  : Best corrected visual acuity. 
2.  IOP  : Intra Ocular Pressure. 
3.  PH  : Pin Hole. 
4.  RE  : Right Eye. 
5.  LE   : Left Eye. 
6.  NVG  : Neo Vascular Glaucoma. 
7.  PDR  :  Proliferative Diabetic Retinopathy. 
8.  ADED  : Advanced Diabetic Eye Disease. 
9.  JCA  :  Juvenile Chronic Arthritis. 
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                                     MASTER CHART 
 
NO  NAME  AGE  DIAGNOSIS  
PREOP 
BCVA & lOP 
(mmHg)  
POSTOP BCVA & 
IOP (mmHg) 6month, 
1 yr, 18 mon, 2yr 
I  Madhava 
prabhu  
52  Post PKP Sec.Glaucoma  6/60 with PH 
6/36 I0P 32  
6/36 with PH 6/18  
16,18,18,16  
2  Mohan 40  BE PDR with  NVG LE PL  
IOP 34  
PL  
16,17,17,19  
3 Kumar 30 Penetrating injury  with 
LE Glaucorna 
CFCF  
I0P 40 
1/60  
8,10,9 
4  Satyamoorthy  47  RE NVG  PL  
IOP 49  
PL  
16,17,17  
5  Siva  56  LE NVG  5/60  
lOP 32  
6/60 NIG NIP  
14,16,15,20  
6  Kantha  60  RE NVG  6/60 NIP 
I0P30  
6/36 NIP  
20,21,22,30   
7  Chinthamani  55  BE PDR with LE NVG  HM  
lOP 32  
HM  
12,11 
8  Penicillammal  60  RE Mature 
CataractwithNVG  
PL  
10P45  
PL  
15,16,16  Vn 6/60 
( post cat. surg.) 
9 George Clive 44 RE NVG 5/60 with PH 
6/60 lOP 40 
6/60 with PH 6/36  
20,17,15,14 
10 Beevi 60 RE immature  
Cataract with  
NVG 
PL  
IOP 52  
Post cataract 
surg 
Shallow AC IOP 40  
6/60, IOP 14 
11 Dayalan 60 LE NVG HM 
IOP 34 
1/60  
20,16 
12 Sundaram 58 BE PDR With LE NVG  
 
5/60 NIP 
 I0P43 
6/60 NIP  
11,12,12 
13 Sivaji 30 Blunt injury RE with 
Resolved Vit Hg. With  
Glaucoma 
PL  
I0P 30 
PL  
9,10.10 
14 Kuruvammal 64 RE NVG 4/60  
IOP 34 
6/60  
14,14 
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15 Ashiq 10 BE – JCA with Pan-
Uveitis with post infl 
Glaucoma BE 
1/60 NIP BE  
IOP 34 RE  
30 LE 
1/60 NIP 12,20,24, 
12,12,14 
16 Duraisamy 59 LE ADED with NVG HM  
lOP 38 
HM  
12,10 
17 Kondaiah 44 Post traumatic glaucoma 
with failed trabeculectomy 
6/60  
I0P34 
6/36  
14,20,30 
18 Mariammal 65 NVG RE PL  
lOP 40 Post 
cataract surg 
6/60  
21,17 
 
19 Raja 30 Post infl. glaucoma 6/60  
IOP 32 
6/24  
21,20 
20 Subramani 56 LE NVG 6/60  
10P 32 
6/60  
14,16 
21 Chandrahasan 45 Post traumatic glaucoma 
with failed trabeculectomy 
5/60 NIP  
10P 34 
6/36 NIP  
22,17 
22 Senthamarai 58 BE PDR with LE NVG HM  
I0P 40 
HM   
12, 11 (3, 6 months) 
23 Kuruvammal 60 LE NVG  HM IOP 38 HM    
20,20 (3, 6 months) 
24 Baby 60 RE NVG 6/60  
I0P 34 
6/36  
14,16 (3, 6 months) 
25 Muniammal 60 RE NVG  PL 
I0P 28 
 PL  
IOP 16, 17 (3, 6 
months) 
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                      LIST OF FEW SURGERIES PERFORMED 
SL 
No 
Name Age Sex IP/OP 
NO Diagnosis 
SURGERY 
1. Raman 53 M 68004 LE-Mature cataract LE-ECCE/PCIOL 
2. Mani 57 M 413926 LE-Nuclear Cataract LE-SICS/PCIOL 
3. Kumar 62 M 65837 RE-Immature 
Cataract 
RE-ECCE/PCIOL 
4. Vimala 73 F 424520 RE-PACG RE-Trabeculectomy 
5. Kantha 52 F 413348 RE-Immature 
Cataract 
RE-SICS/PCIOL 
6. Ganesan 65 M 426626 LE-Secondary angle 
closure Glaucoma 
LE-Combined 
Surgery 
7. Komala 35 F 411184 LE-Conjunctival tear LE-Conjunctival 
Suturing 
8. Pushpa 18 F 69004 RE-Pterygium RE-
Excision/Autograft 
9. Natarajan 27 M 41234 LE-Rupture Globe LE-Corneoscleral 
suturing 
10. Thangaraj 61 M 416599 RE-Panophthalmitis RE-Evisceration 
11. Valli 28 F 64287 RE-Lower lid 
Chalazion 
RE-Incision and 
curettage 
12. Kesavan 73 M 68905 LE-Pterygium LE-Pterygium 
Excision/Autograft 
13. Ganesh 45 M 56432 RE-Chronic 
dacrocystitis 
RE-DCT 
14. Thulasi 62 F 62346 RE-Nuclear Cataract RE-ECCE/PCIOL 
15. Rajesh 43 M 65749 RE-Chronic 
dacrocystitis 
RE-DCT 
16. Jagadambal 56 F 15281 LE-Immature 
Cataract 
LE-SICS/PCIOL 
17. Kavitha 54 F 17865 LE-Immature 
Cataract 
LE-SICS/PCIOL 
18. Hariharan 76 M 69045 LE-Chronic 
dacrocystitis 
LE-DCT 
19. Ramanathan 34 M 564781 RE-Lowerlid 
granuloma 
Excision 
20. Kulesekar 48 M 45367 RE-Pterygium RE-Pterygium 
Excision/Autograft 
21. Kala 52 F 456390 RE-Immature 
Cataract 
RE-SICS/PCIOL 
22. Ramiah 65 M 421184 LE-Mature cataract LE-ECCE/PCIOL 
23. Chidambaram 64 M 60897 RE-Chronic 
dacrocystitis  
RE-DCT 
